MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2

MicroRNA-630 (miR-630) plays dual roles in tumor progression in various human cancers. However, the role of miR-630 in chemoresistance and prognosis in non-small cell lung cancer (NSCLC) remains to be elucidated. This retrospective study enrolled 114 surgically resected patients with NSCLC who exper...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ming-Jenn, Wu, De-Wei, Wang, Gao-Chang, Wang, Yao-Chen, Chen, Chi-Yi, Lee, Huei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862613/
https://www.ncbi.nlm.nih.gov/pubmed/29568392
http://dx.doi.org/10.18632/oncotarget.24474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862613/
https://www.ncbi.nlm.nih.gov/pubmed/29568392
http://dx.doi.org/10.18632/oncotarget.24474

Ejemplares similares